Quest Diagnostics Expects 2024 Sales Of $9.80B-$9.85B Versus Consensus Of $9.67B
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics has updated its 2024 sales guidance to $9.80B-$9.85B, surpassing the consensus of $9.67B. The update accounts for recent acquisitions and the impact of Hurricane Milton, which is expected to reduce Q4 net revenues by $15 million and EPS by 8 cents.
October 22, 2024 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has raised its 2024 sales guidance to $9.80B-$9.85B, exceeding the consensus estimate of $9.67B. This reflects the impact of recent acquisitions and a $15 million revenue hit from Hurricane Milton in Q4.
The updated guidance surpasses market expectations, which is generally positive for stock prices. The impact of acquisitions is seen as a growth driver, while the negative impact from Hurricane Milton is relatively minor.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100